

Inofer

[Iron (III) Hydroxide polymaltose complex]

50mg/5ml Syrup

Composition:

Each 5ml contains
Iron (III) Hydroxide polymaltose complex
eq. to Elemental iron 50 mg
Product Complies Innovator's Specs.

DESCRIPTION

The iron (III)–hydroxide polymaltose complex (IPC) is a water-soluble iron oxide, macromolecular complex of polynuclear iron (III) hydroxide and partially hydrolysed dextrin (polymaltose).

PROPERTIES

IPC (Inofer) syrup is an iron preparation for the treatment of latent iron deficiency and iron deficiency anaemia. Iron is an important constituent of haemoglobin, myoglobin, and the enzymes that contain iron. The treatment of iron deficiency in infants up to one year of age is of extreme importance. Iron deficiency at this age can impair the development of the brain. In general, iron deficiency can cause chronic fatigue, lack of concentration, irritability, nervousness, headache, loss of appetite, susceptibility to stress and infection, paleness, cracks at the corners of the mouth (rhagades), dry skin, brittle hairs and nails as well as loss of interest in play in children. The iron in Inofer syrup exists as iron (III)-hydroxide complex, where individual particles are embedded into a carbohydrate polymer (polymaltose). This prevents the iron from causing any harm in the gastrointestinal system. This protection inhibits interactions of the iron with food. Moreover, it ensures the bioavailability of the iron. The structure of IPC is similar to ferritin, the naturally occurring iron storage protein. Due to this similarity, iron is absorbed through natural mechanism. IPC has no pro-oxidative properties such as there are with bivalent iron salts.

INDICATIONS

Prevention and treatment of all kinds of iron deficiencies particularly iron deficiency anaemia. The liquid formulation is specially for the prophylactic therapy of iron deficiency to cover the recommended daily allowance (RDA) during pregnancy & lactation, for children, adolescents, women capable of bearing children, and adults.

DOSAGE & ADMINISTRATION

Dosage and duration of therapy are dependent upon the extent of iron deficiency. The daily dose can be divided into separate doses or can be taken at one time during or after meal. IPC (Inofer) syrup can be mixed with fruit and vegetable juices or with bottle-feed. The slight colouration does not affect either the taste or the efficacy.

	Manifest iron deficiency	Latent iron deficiency	Prophylactic therapy (RDA)
Infants (up to 1 year)	2.5-5 ml daily (25-50 mg iron)	—	—
Children (1 - 12 year)	5-10 ml daily (50-100 mg iron)	2.5-5 ml daily (25-50 mg iron)	—
Children (1 - 12 year), adults & nursing mothers	10-30 ml daily (100-300 mg iron)	5-10 ml daily (50-100 mg iron)	—
Pregnant Women	20-30 ml daily (200-300 mg iron)	10 ml daily (100 mg iron)	Prophylactic therapy (RDA)

In case of manifest iron deficiency the therapy takes about 3-5 months until a normalization of the haemoglobin value is achieved. Afterwards the therapy should be continued for several weeks or for pregnant women, at least until the end of the pregnancy with a dosage such as described for latent iron deficiency to replenish the iron stores.

In case of latent iron deficiency the therapy takes about 1-2 months.

CONTRA-INDICATIONS

Iron overload (e.g. haemochromatosis, haemosiderosis) or disturbances in iron utilization (e.g. lead anaemia, sidero-achrestic anaemia, thalassaemia) and anaemia not caused by iron deficiency (e.g. haemolytic anaemia).

INTERACTIONS

Until now interactions have not been observed. Since the iron is complex-bound, ionic interactions with food components (phytin, oxalates, tannin etc.) and concomitant administration of medicaments (tetracyclines, antacids) are unlikely to occur. The haemocult test (selective for Hb) for the detection of occult blood is not impaired and therefore there is no need to interrupt iron therapy.

PREGNANCY AND LACTATION

Pregnancy category A Reproduction studies in animals did not show any foetal risk. Controlled studies in pregnant women after the first trimester have not shown any undesirable effects on mother and neonates. There is no evidence

انوفر ۵۰ ملی لیٹر
سیرپ

of a risk during the first trimester and a negative influence on the foetus is unlikely. Mother's milk contains iron bound to lactoferrin. It is not known how much iron from the complex is passed into mother's milk. The administration of IPC is unlikely to cause undesirable effects to the nursed child. During pregnancy and lactation IPC should be used only after consulting a medical doctor or pharmacist.

UNDESIRABLE EFFECTS

Occasionally gastrointestinal irritations such as a sensation of repletion, pressure in the epigastric region, nausea, constipation or diarrhoea can occur. A dark colouration of the stool due to iron is of no clinical significance. IPC (Inofer) syrup does not cause teeth staining.

OVERDOSE

In cases of overdose neither intoxication nor iron overload have been reported to date.

PRESENTATION

Inofer 50 mg/5 ml syrup is available in 60ml bottle.

STORAGE CONDITIONS AND INSTRUCTIONS

- Store below 30° C in a dry place, protect from light.
- To be dispensed on the prescription of a registered medical practitioner only.
- Keep out of the reach of children.

ہدایات:

- **خوراک** ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
- دوا کو ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر روشنی سے بچا کر خشک جگہ پر رکھیں۔
- صرف رجسٹرڈ ڈاکٹر کے نسخے پر ہی فروخت کریں۔
- بچوں کی پہنچ سے دور رکھیں۔

Manufactured by:

Kaizen Pharmaceuticals (Pvt.) Ltd.
E-127-129, North Western Industrial Zone,
Bin Qasim, Karachi-75020, Pakistan.

ART No: 426/1